

AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.121

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

Claims 1-26 (Cancelled)

27. (New) A method for the inhibition of PDE3 in the tissues of a patient comprising:
- a. providing:
 - i. a patient having tissues producing PDE3 and,
 - ii. monochloroflosequinan sulfone (3-chloromethylsulfonyl-7-fluoro-1-methyl-4-quinolone); and
 - b. administering said monochloroflosequinan sulfone under conditions such that the production of said PDE3 is inhibited in the tissues of said patient.
28. (New) The method, as claimed in claim 27, wherein said tissues are selected from the group consisting of blood.
29. (New) A method for the inhibition of PDE1 in the tissues of a patient comprising:
- a. providing:
 - i. a patient having tissues producing PDE1 and,
 - ii. monochloroflosequinan (3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone); and
 - b. administering said monochloroflosequinan under conditions such that the production of said PDE1 is inhibited in the tissues of said patient.
30. (New) The method, as claimed in claim 29, wherein said tissues are selected from the group consisting of heart tissue.

31. (New) A method for the inhibition of PDE2 in the tissues of a patient comprising:
 - a. providing:
 - i. a patient having tissues producing PDE2 and,
 - ii. monochloroflosequinan (3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone); and
 - b. administering said monochloroflosequinan under conditions such that the production of said PDE2 is inhibited in the tissues of said patient.
32. (New) The method, as claimed in claim 31, wherein said tissues are selected from the group consisting of blood.
33. (New) A method for the inhibition of PDE3 in the tissues of a patient comprising:
 - a. providing:
 - i. a patient having tissues producing PDE3 and,
 - ii. monochloroflosequinan (3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone); and
 - b. administering said monochloroflosequinan under conditions such that the production of said PDE3 is inhibited in the tissues of said patient.
34. (New) The method, as claimed in claim 33, wherein said tissues are selected from the group consisting of blood.